Ocular Therapeutix announces topline results of phase 3 trial of dextenza for treatment of ocular itching associated with allergic conjunctivitis

Ocular Therapeutix announced topline results from its Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis (AC).